IPO Update: Juno has biggest 2014 offering as investors chase CAR-T stocks
This article was originally published in Scrip
Juno Therapeutics had the biggest biotechnology initial public offering of 2014 and its stock closed 45.8% above the IPO price on 19 December, the company's first day of trading, showing how intensely interested investors have become in chimeric antigen receptor T-cell (CAR-T) therapies.
You may also be interested in...
Private Company Edition: Former Juno execs launch allogeneic cell therapy venture Sana, Atlas raises a $250m fund, and the Rakuten Aspyrian, Apollomics and Antengene VC deals exceed the $100m mark.
Juno and partner Celgene closed the ROCKET study for JCAR015, which has been on clinical hold since November, and ended development in ALL in favor of its new and improved CD19-targeting CAR-T therapies.
ARCH invests $150m in the Scangos-led Vir Biotechnology; Flagship recruits ex-Novartis executive Epstein; Versant closes a new $400m fund; and $601.1m in 11 other recent VC funding rounds.